Contact
About Abbott
cardiovascular
MY ACCOUNT

XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

Unparalleled Safety

Unparalleled Safety with XIENCE™ Stent1

XIENCE™ Stent's Excellent Outcomes in Complex Patients2-4

Early outcomes with XIENCE™ Stent, implanted in complex patients, reveal excellent rates of definite stent thrombosis (ST) at 30 days:

    • Bifurcations Lesions: 0.0%2
    • Calcified Lesions: 0.0%3
    • Long Lesions: 0.3% ST4
    XIENCE Stent

    Lower Early Stent Thrombosis Rates with XIENCE™ Stent vs Other DES

    XIENCE™ Stent Acute ST Rate 75% Lower vs Other DES

    With XIENCE™ Stent there is a 75% lower rate of acute (24-hour) definite ST compared to Synergy‡.5

    Acute definite ST is 75% lower with XIENCE Stent vs Synergy: 0.3% with XIENCE Stent and 1.2% with Synergy.


    XIENCE™ Stent Early ST Rate 88% Lower vs Other DES

    With XIENCE™ Stent there is an 88% lower rate of early (30-day) definite ST compared to Resolute‡.6

    Early definite ST is 88% lower with XIENCE Stent vs Resolute: 0.1% with XIENCE Stent and 0.8% with Resolute.

    Consistently Lowest Rates of Late and Very Late Stent Thrombosis

    XIENCE™ Stent has the most exceptional rates—and consistently the lowest rates—of late and very late ST.1 It’s another example of how XIENCE™ Stent delivers unparalleled patient outcomes which last far beyond the intervention.1


    Even when examining ultra-long-term safety, XIENCE™ Stent reveals excellent patient outcomes—0.8% ST 10 years after PCI.12

    At 10 years, XIENCE Stent has revealed 0.8% stent thrombosis rates.
    Explore Abbott's technologies for your needs.

    Explore Abbott's technologies for your needs.

    Access personalised education and training

    Access personalised education and training

    How can we help? Reach Abbott’s fast support here.

    How can we help? Reach Abbott’s fast support here.

    References

    1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
    2. Džavík V, et al. Catheter Cardiovasc Interv. 2013;82(3):E163-E172.
    3. Onuma Y, et al. Catheter Cardiovasc Interv. 2010;76:634-642.
    4. Hong S, et al. JACC Cardiovasc Interv. 2016;9:1438-1446.
    5. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675.
    6. Serruys P, et al. N Engl J Med. 2010;363:136-146.
    7. von Birgelen C, et al. J Am Coll Cardiol. 2012;59:1350-1361.
    8. Natsuaki M, et al. Cardiovasc Interv Ther. 2016 31(3):196-209.
    9. van Geuns RJ, et al. TCT 2019. IDEAL-LM.
    10. Chevalier B, et al. EuroIntervention. 2018;13:1561-1564.
    11. Gao R, et al. TCT 2019. ABSORB China.
    12. Kufner S, et al. Circulation. 2019:139(3):325-333.

    MAT-2413628 V1.0

    POLICIES
    LOGIN & REGISTRATION
    Abbott logo

    Information contained herein for distribution in Australia and New Zealand only.
    CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.
    Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.
    Abbott Vascular division of Abbott Medical New Zealand Ltd, Grd Flr, Bldg. D, 4 Pacific Rise Mt Wellington, Auckland 1060 Tel: 0800 827 285
    Abbott Vascular division of Abbott Medical Australia Pty Ltd, 299 Lane Cove Road, Macquarie Park NSW 2113, Tel: 1800 550 939
    © 2025 Abbott. All Rights Reserved.
    MAT-2105201 v7.0

    Disclaimer

    You are about to enter an Abbott country or region specific website.

    Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

     

    Do you wish to continue and enter this website?

    MAT-2105201 v1.0

    Disclaimer

    You are about to enter an Abbott country or region specific website.

    Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

     

    Do you wish to continue and enter this website?

    MAT-2105201 v1.0